Hemostasis and Tissue Sealing Agents Market

World Health Organization (WHO) projects that the global count of people aged above 65 years, will reach 2 billion by 2050. With the rising geriatric populations, due to several age related conditions, there will be more surgical procedures, which will increase the demand for hemostasis and tissue sealing agents. Hemostasis and tissue sealing agents are used to prevent hemorrhage. During a surgery it is very important to stop the excessive bleeding of the patient, to avoid further damage or death by blood loss. This has created the need for hemostasis and tissue sealing agents. The increasing number of surgeries, introduction of multi-usage and ready-to-use products along with the global rise in geriatric populations supplement the growth of the global hemostasis and tissue sealing agents market during the analysis period. Recently, the FDA has approved numerous hemostatic products that would further drive the growth of global hemostasis and tissue sealing agents market. Factors restraining the market growth are high prices of the products and stringent regulatory environment.

The global hemostasis and tissue sealing agents market, is segmented on the basis of product type and geography. The product types considered, in this report include Topical Hemostats and Adhesive and Tissue Sealing Agents. Topical Hemostats are further classified into Mechanical Hemostats, Active Hemostats, Flowable Hemostats, Fibrin Sealants and Topical Thrombin Products. Adhesive and Tissue Sealing Agents are further classified into Natural Tissue Sealants, Synthetic Tissue Sealants and Adhesion Barrier Products. Geographically, the market is segmented into four regions namely North America, Europe, Asia Pacific and LAMEA. One of the strategies adopted by major market players is product launch. For instance, in 2013, Baxter Launched Hemopatch, which is an Innovative Sealing Hemostat. This easy to use product (has helped the company gain competitiveness in the European market. The companies profiled in this report are Johnson & Johnson, CryoLife, Baxter, Cohera Medical, Omrix Biopharmaceuticals, Advance Medical Solution Group, Entegrion, Cryolife, Bioster and Nycomed.

KEY MARKET BENEFITS:

• The report provides a quantitative analysis of the current market and estimations which would enable the stakeholders to capitalize on prevailing market opportunities
• Extensive analysis of the global apheresis equipment market by product type helps in understanding the types of equipment that are currently used along with the variants that would gain prominence in future
• Competitive intelligence highlights the business practices followed by leading market players across various geographies
• Comprehensive analysis of factors that drive and restrict the growth of the global apheresis equipment market is provided
• SWOT analysis highlights the internal environment of leading companies for effective strategy formulation
• The apheresis equipment market scenario is comprehensively analysed in accordance to the key regions

 Hemostasis and Tissue Sealing Agents Market Report Highlights